Search Results - "Angelelli, B."

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases by Cosimelli, M, Golfieri, R, Cagol, P P, Carpanese, L, Sciuto, R, Maini, C L, Mancini, R, Sperduti, I, Pizzi, G, Diodoro, M G, Perrone, M, Giampalma, E, Angelelli, B, Fiore, F, Lastoria, S, Bacchetti, S, Gasperini, D, Geatti, O, Izzo, F

“…Background: This multi-centre phase II clinical trial is the first prospective evaluation of radioembolisation of patients with colorectal liver metastases…”
Get full text

Selective arterial embolisation for bone tumours: experience of 454 cases by Rossi, G., Mavrogenis, A. F., Rimondi, E., Ciccarese, F., Tranfaglia, C., Angelelli, B., Fiorentini, G., Bartalena, T., Errani, C., Ruggieri, P., Mercuri, M.

“…Purpose The authors present the experience of a single institution with selective arterial embolisation for primary and metastatic bone tumours. Materials and…”
Get full text

Retrospective analysis of dose–response for HCC lesions treated with 90Y resin microspheres by Pettinato, C, Mosconi, C, Cappelli, A, Civollani, S, Pini, P, Monari, F, Angelelli, B, Nobili, E, Fanti, S, Golfieri, R

Get full text

Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study by Martoni, A, Mini, E, Pinto, C, Gentile, A L, Nobili, S, Dentico, P, Marino, A, Scicolone, S, Angelelli, B, Mazzei, T

“…The combination of Oxaliplatin (OXA) and Raltitrexed (RTX) may represent a more convenient regimen as compared with OXA + 5-FU with Folinic acid (FA)…”
Get more information

Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma by Martoni, A., Mini, E., Pinto, C., Nobili, S., Gentile, A. L., Dentico, P., Angelelli, B., Scicolone, S., Piana, E., Mazzei, T.

“…Background Both OHP and 5-FU are clinically active as single agents in the treatment of metastatic colorectal cancer (MCRC) Clinical and laboratory studies…”
Get full text

An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens by Martoni, A., Angelelli, B., Guaraldi, M., Strocchi, E., Pannuti, F.

“…The aim of the study was to compare granisetron (GRA) with ondansetron (OND) in the prevention of acute emesis in consecutive chemotherapy-naive patients…”
Get full text

The impact of the clinical pharmacist (CP) in reporting suspected adverse drug reactions (ADRs): the experience of the Medical Oncology Unit at the S.Orsola-Malpighi University Hospital by Grilli, D., Gelsomino, F., Massari, F., Angelelli, B., Tognetto, M., Restuccia, S., Puggioli, C., Ardizzoni, A.

Get full text

Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis by Martoni, A, Piana, E, Strocchi, E, Angelelli, B, Guaraldi, M, Zamagni, C, Camaggi, C M, Pannuti, F

“…The 5HT3 receptor antagonist Granisetron (GRA) is available on the market as a 1 mg vial in USA and as a 3 mg vial in Europe. This study aimed to compare the…”
Get more information

C.375 - Retrospective analysis of dose–response for HCC lesions treated with 90Y resin microspheres by Pettinato, C., Mosconi, C., Cappelli, A., Civollani, S., Pini, P., Monari, F., Angelelli, B., Nobili, E., Fanti, S., Golfieri, R.

Get full text

A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma by Martoni, A, Panetta, A, Angelelli, B, Melotti, B, Pannuti, F

“…Forty-two patients affected by either stage III and IV ovarian cancer with residual tumor after surgery or recurrent ovarian cancer entered a phase II study of…”
Get more information

Chemotherapy of advanced ovarian cancer by Martoni, A, Cacciari, N, Angelelli, B, Zamagni, C, Pannuti, F

“…Majority of ovarian cancer patients have advanced disease (stage III or IV) at diagnosis and the prognosis of these patients is poor in spite of aggressive…”
Get full text

Selective arterial embolisation for bone tumours: experience of 454 cases L'embolizzazione arteriosa selettiva dei tumori ossei: esperienza in 454 casi by Rossi, G, Mavrogenis, A F, Rimondi, E, Ciccarese, F, Tranfaglia, C, Angelelli, B, Fiorentini, G, Bartalena, T, Errani, C, Ruggieri, P

“…Purpose The authors present the experience of a single institution with selective arterial embolisation for primary and metastatic bone tumours…”
Get full text

Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients by Camaggi, C M, Strocchi, E, Martoni, A, Angelelli, B, Comparsi, R, Pannuti, F

“…Plasma and whole blood pharmacokinetics of epirubicin (4'-epidoxorubicin, epiDX), a new doxorubicin (DX) analogue with an improved spectrum of activity and…”
Get more information

Neoadjuvant chemotherapy in cervical carcinoma : Regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome by COSTA, Silvano, TERZANO, Patrizia, ERZEN, Mojca, SYRJÄNEN, Stina, SYRJÄNEN, Kari, SANTINI, Donatella, CECCARELLI, Claudio, MARTONI, Andrea, ANGELELLI, Bruna, PANETTA, Achille, BOVICELLI, Alessandro, CRISTIANI, Paolo, LIPPONEN, Pertti

“…To evaluate whether cellular markers predict the responsiveness to neoadjuvant chemotherapy (NAC) in cervical cancer, 21 patients with stages I and II cervical…”
Get full text

CD44 Isoform 6 (CD44v6) Is a Prognostic Indicator of the Response to Neoadjuvant Chemotherapy in Cervical Carcinoma by Costa, Silvano, Terzano, Patrizia, Bovicelli, Alessandro, Martoni, Andrea, Angelelli, Bruna, Santini, Donatella, Ceccarelli, Claudio, Lipponen, Pertti, Erzén, Mojca, Syrjänen, Stina, Syrjänen, Kari

“…Objective. Theclinical efficacy of neoadjuvant chemotherapy (NAC) in distinct groups of cervical cancer patients has been well documented, but parameters at…”
Get full text

Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration by Strocchi, E, Camaggi, C M, Rossi, A P, Angelelli, B, Comparsi, R, Franchini, A, Del Prete, P, Cola, B, Pannuti, F

“…The high hepatic clearance of the new doxorubicin analogue epirubicin (4'-epidoxorubicin, epiDX) suggests a possible use of this drug in local and regional…”
Get more information

A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study by Pannuti, F, Iafelice, G, Martoni, A, Fruet, F, Angelelli, B, Casadei, M

“…Two groups of 23 patients each, having advanced breast cancer, entered this prospective and randomized study. One group was treated with the conventional…”
Get more information

The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients by Lelli, G, Angelelli, B, Zanichelli, L, Strocchi, E, Mondini, F, Monetti, N, Piana, E, Pannuti, F

“…Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were treated with high dose medroxyprogesterone acetate (MAP,…”
Get more information

The anabolic effect of high dose medroxyprogesterone acetate in oncology by Lelli, G, Angelelli, B, Giambiasi, M E, Colalongo, F, Camaggi, C M, Costanti, B, Strocchi, E, Pannuti, F

“…Ten advanced cancer patients not amendable to conventional therapy were treated with high dose (greater than 500 mg/day, for 30 days) Medroxyprogesterone…”
Get more information

Pilot study on induction chemotherapy with cisplatin, epirubicin, etoposide and bleomycin in cervical cancer stage Ib, IIa and IIb by Panetta, A, Angelelli, B, Martoni, A

“…Induction chemotherapy, consisting of 3 courses of cisplatin (30 mg/m2/i.v. 1st and 2nd day), epirubicin (30 mg/m2/i.v. 1st and 2nd day), etoposide (75…”
Get more information